NCT01446133View on ClinicalTrials.gov

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 12, 2011

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
LeukemiaLymphoma
Interventions
DRUG

Rituximab

375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.

DRUG

Lenalidomide

10 mg/day by mouth daily beginning on Day 9 of cycle 1.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER